IDEMIA
1.10.2020 11:59:07 CEST | Business Wire | Press release
IDEMIA, the global leader in Augmented Identity, today announces its GREENPAY launch, an eco-friendly global offer for financial institutions, in line with its CSR* and sustainability strategy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201001005547/en/
Environmental concerns underpin IDEMIA’s business practices. Through GREENPAY, IDEMIA commits to move away from today’s “take-make-waste” attitude to redesign our habits. IDEMIA is proud to develop solutions generating less plastic and paper waste, reducing land and water pollution while also minimizing its carbon footprint.
GREENPAY is IDEMIA’s commitment to continuously improve each part of the payment card value chain, seeking to:
- Minimize the environmental impact of its processes and services
- Develop innovative, eco-friendly products, services and solutions
- Help customers achieve their environmental goals with IDEMIA’s product offering.
GREENPAY encompasses eco-friendly card body solutions, advanced card related services like eco-designed packaging, on-demand printing of PEFC/FSC certified card carrier, digital alert and e-documents among other services that enable financial institutions to deploy their sustainability transformation.
Over the last few months, IDEMIA’s customers around the world, including Latin America, the US, Europe and Asia, have adopted GREENPAY. For example:
- The RHB 1 Visa WWF Debit Card-i is a recycled PVC payment card which will be available to all new and existing RHB customers in Malaysia from July 2020. The cards contain state-of-the-art technology for seamless payments, have passed all durability tests and are ISO-certified and EMV compliant.
- IDEMIA’s trusted solutions were chosen to accompany BBVA ’s2 customers in the environmental transition journey. This partnership will progressively allow the bank to deliver cards made of “eco friendly” materials to customers in all countries where it has a presence by the end of 2021.
- IDEMIA also offers Treezor 3 , a low-natural-resource-consuming card which does not compromise on security or end-user convenience. The collaboration between IDEMIA and Treezor - French banking-as-a-service market leader - has culminated in the launch of the first ever eco-friendly card by a FinTech in France.
- IDEMIA was also awarded the “Environmental Claim Validation Summary” certification by its recycled PVC supplier “UL Environment Inc.”
Furthermore all GREENPAY products & services – through IDEMIA’s certified partner – financially contribute to key environmental projects around the world in line with the Sustainable Development Goals set up by the United Nations.
IDEMIA’s Executive VP Financial Institutions Amanda Gourbault said: “We at IDEMIA take sustainable development very seriously and believe the financial community is perfectly placed to promote green initiatives and build a better tomorrow. This is GREENPAY’s primary objective, combining all our expertise in technologies which further CSR goals.”
*CSR: Corporate Social Responsibility
About IDEMIA
IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter
1
See PR - https://www.idemia.com/press-release/idemia-partners-rhb-bank-launch-first-recycled-debit-card-asia-pacific-2020-06-15
2
See PR - https://www.idemia.com/press-release/idemia-and-bbva-partner-launch-spains-first-payment-card-made-recycled-pvc-2020-06-05
3
See PR - https://www.idemia.com/press-release/idemia-and-treezor-launch-first-eco-friendly-payment-card-onlyone-french-fintech-firm-2020-06-26
View source version on businesswire.com: https://www.businesswire.com/news/home/20201001005547/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
First Randomized Controlled Trial Shows Promise of a Ketogenic Diet in Psychotic Disorders8.7.2026 15:00:00 CEST | Press release
Trial reports correlations between ketone levels and cognitive and psychiatric symptoms in individuals with schizophrenia-spectrum and bipolar-1 disorders Published today in Schizophrenia Bulletin, a first-of-its-kind randomized controlled trial (RCT) from researchers at the University of California, San Francisco (UCSF), and funded in part by the National Institute of Mental Health (NIMH), adds to growing literature on the potential benefit of a ketogenic diet for treating psychotic disorders. The study, which enrolled participants with schizophrenia-spectrum or bipolar-1 disorders, demonstrated rapid metabolic improvements with a ketogenic diet compared to diet-as-usual during an initial one-month RCT open-label phase. Furthermore, those who continued with the optional four-month single-arm ketogenic diet extension saw meaningful gains across metabolic, psychiatric, and cognitive measures. This press release features multimedia. View the full release here: https://www.businesswire.co
Teamily AI Publicly Launches Human+AI Social Platform to Make Building and Growing a Company Easy for Every Team8.7.2026 15:00:00 CEST | Press release
Teamily AI (https://Teamily.ai), together with its Agentic AI Infra platform TensorOpera AI (https://TensorOpera.ai), today announced the public launch of its Human+AI social platform, a product stack that has already served more than 5 million users around the world. Starting today in Palo Alto and rolling out simultaneously across dozens of countries, this first public launch opens the full stack to everyone with a single mission: to make building and growing a company easy for every person and every team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708584390/en/ "This is the moment we open our doors to the world," said co-founders Dr. Aiden Chaoyang He and Professor Salman Avestimehr. "We want every person and every team to be able to move from idea to product, from product to market, and from market to growth and investment, with an AI-native team by their side." At its core, Teamily AI enables humans and AI agents
Leo Cancer Care Raises $65M Series D to Scale Its Integrated Upright Cancer Care Platform8.7.2026 14:30:00 CEST | Press release
Oversubscribed round follows the world-first compact upright proton treatment at Stanford Medicine — funding a single upright platform that will span imaging and treatment across multiple radiation modalities. Leo Cancer Care, the medical technology company working to reinvent how patients are imaged and treated by designing systems around the body’s natural upright position, today announced the close of an oversubscribed $65 million Series D financing. The round was led by Silicon Valley’s Yu Galaxy and welcomes new investors including Eventide Asset Management, alongside continued support from the company’s existing investors. Leading cancer institutions are already adopting the upright approach. Stanford Medicine delivered the world’s first compact upright proton therapy treatment on 4 June 2026. Dana-Farber Cancer Institute and McLaren Health Care are among the institutions bringing the upright platform into their programmes — adoption that spans world-leading academic centers and
LUMI AI Factory Selects IQM to Deploy Advanced Quantum Computer, Accelerating Hybrid HPC and AI Development8.7.2026 14:00:00 CEST | Press release
The Halocene H4 quantum computer, named LUMI-IQ, will be delivered and installed in 2027 The system will be hosted at CSC – IT Center for Science in Finland and integrated into the LUMI AI Factory The system will provide researchers, industry innovators, and developers across Europe with a unique, advanced experimental platform where quantum computing and artificial intelligence converge The LUMI AI Factory, led by CSC – IT Center for Science, has selected IQM Quantum Computers (Nasdaq: IQMX) to deliver IQM Halocene H4, an advanced quantum computer aimed at accelerating hybrid high-performance computing, artificial intelligence, and quantum computing capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708006791/en/ LUMI AI Factory selects IQM to deploy advanced quantum computer, accelerating hybrid HPC and AI development IQM Halocene H4 is the first and most advanced on-premises superconducting quantum computer o
Merck Announces FDA Breakthrough Therapy Designation for Enpatoran in Lupus Patients With Active Skin Manifestations8.7.2026 14:00:00 CEST | Press release
Enpatoran could address a significant unmet need in lupus, specifically targeting cutaneous manifestations of the disease, which currently have no approved therapiesFDA's decision was supported by Phase 2 WILLOW study results, which demonstrated meaningful symptoms improvement, particularly among patients with active cutaneous manifestationsEnpatoran's potential to go beyond current treatment standards in lupus prompted FDA´s breakthrough designation, which is designed to expedite drug development and reviewNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to enpatoran for the treatment of lupus with active cutaneous manifestations. Enpatoran is an oral selective toll-like receptor (TLR) 7/8 inhibitor, designed to modulate pathways central to lupus-related inflammation. “For the 85% of lupus patients whose disease includes skin manif
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom